NURIX THERAPEUTICS, INC. Revenues
NURIX THERAPEUTICS, INC. (NRIX) reported Revenues of $16.59 million for the 3-month period ending 2024-02-29, per its 10-Q filed 2024-04-10.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2024-04-10
- NURIX THERAPEUTICS, INC. revenues for the quarter ending 2024-02-29 was $16.59M, a 30.74% increase year-over-year.
- NURIX THERAPEUTICS, INC. revenues for the quarter ending 2023-11-30 was $15.16M, a 123.49% increase year-over-year.
- NURIX THERAPEUTICS, INC. revenues for the quarter ending 2023-08-31 was $18.47M, a 71.13% increase year-over-year.
- NURIX THERAPEUTICS, INC. revenues for the quarter ending 2023-05-31 was $30.68M, a 168.33% increase year-over-year.
- NURIX THERAPEUTICS, INC. revenues for fiscal 2023 was $76.99M, a 99.31% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. revenues for fiscal 2022 was $38.63M, a 29.84% increase from fiscal 2021.
- NURIX THERAPEUTICS, INC. revenues for fiscal 2021 was $29.75M, a 66.95% increase from fiscal 2020.
- NURIX THERAPEUTICS, INC. revenues for fiscal 2020 was $17.82M, a 42.73% decline from fiscal 2019.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2024-02-29 | $16.59M 10-Q · filed 2024-04-10 | $31.74M derived: sum of 2 quarters · filed 2024-04-10 | $50.21M derived: sum of 3 quarters · filed 2024-04-10 | $80.89M derived: sum of 4 quarters · filed 2024-04-10 |
| 2023-11-30 | $15.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $33.63M derived: sum of 2 quarters · filed 2024-02-15 | $64.30M derived: sum of 3 quarters · filed 2024-02-15 | $76.99M 10-K · filed 2024-02-15 |
| 2023-08-31 | $18.47M 10-Q · filed 2023-10-12 | $49.14M derived: sum of 2 quarters · filed 2023-10-12 | $61.83M 10-Q · filed 2023-10-12 | $68.61M derived: sum of 4 quarters · filed 2024-04-10 |
| 2023-05-31 | $30.68M 10-Q · filed 2023-07-13 | $43.36M 10-Q · filed 2023-07-13 | $50.14M derived: sum of 3 quarters · filed 2024-04-10 | $60.94M derived: sum of 4 quarters · filed 2024-04-10 |
| 2023-02-28 | $12.69M 10-Q · filed 2024-04-10 | $19.47M derived: sum of 2 quarters · filed 2024-04-10 | $30.26M derived: sum of 3 quarters · filed 2024-04-10 | $41.69M derived: sum of 4 quarters · filed 2024-04-10 |
| 2022-11-30 | $6.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $17.57M derived: sum of 2 quarters · filed 2024-02-15 | $29.01M derived: sum of 3 quarters · filed 2024-02-15 | $38.63M 10-K · filed 2024-02-15 |
| 2022-08-31 | $10.79M 10-Q · filed 2023-10-12 | $22.22M derived: sum of 2 quarters · filed 2023-10-12 | $31.84M 10-Q · filed 2023-10-12 | $39.24M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | $11.43M 10-Q · filed 2023-07-13 | $21.05M 10-Q · filed 2023-07-13 | $28.45M derived: sum of 3 quarters · filed 2023-07-13 | $38.70M derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | $9.62M 10-Q · filed 2023-04-13 | $17.02M derived: sum of 2 quarters · filed 2023-04-13 | $27.27M derived: sum of 3 quarters · filed 2023-04-13 | $34.36M derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | $7.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $17.65M derived: sum of 2 quarters · filed 2023-02-09 | $24.74M derived: sum of 3 quarters · filed 2023-02-09 | $29.75M 10-K · filed 2023-02-09 |
| 2021-08-31 | $10.25M 10-Q · filed 2022-10-06 | $17.34M derived: sum of 2 quarters · filed 2022-10-06 | $22.35M 10-Q · filed 2022-10-06 | $29.04M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | $7.09M 10-Q · filed 2022-07-07 | $12.10M 10-Q · filed 2022-07-07 | $18.79M derived: sum of 3 quarters · filed 2022-07-07 | $22.88M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | $5.01M 10-Q · filed 2022-04-08 | $11.70M derived: sum of 2 quarters · filed 2022-04-08 | $15.79M derived: sum of 3 quarters · filed 2022-04-08 | $19.97M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | $6.69M 10-K · filed 2021-02-16 | $10.77M derived: sum of 2 quarters · filed 2021-10-14 | $14.96M derived: sum of 3 quarters · filed 2021-10-14 | $17.82M 10-K · filed 2022-01-28 |
| 2020-08-31 | $4.08M 10-Q · filed 2021-10-14 | $8.27M derived: sum of 2 quarters · filed 2021-10-14 | $11.13M 10-Q · filed 2021-10-14 | $12.99M derived: sum of 4 quarters · filed 2021-10-14 |
| 2020-05-31 | $4.18M 10-Q · filed 2021-07-13 | $7.05M 10-Q · filed 2021-07-13 | $8.91M derived: sum of 3 quarters · filed 2021-07-13 | $19.49M derived: sum of 4 quarters · filed 2021-07-13 |
| 2020-02-29 | $2.86M 10-Q · filed 2021-04-13 | $4.73M derived: sum of 2 quarters · filed 2021-04-13 | $15.31M derived: sum of 3 quarters · filed 2021-04-13 | $24.75M derived: sum of 4 quarters · filed 2021-04-13 |
| 2019-11-30 | $1.86M 10-K · filed 2021-02-16 | $12.44M derived: sum of 2 quarters · filed 2021-02-16 | $21.88M derived: sum of 3 quarters · filed 2021-02-16 | $31.11M 10-K · filed 2022-01-28 |
| 2019-08-31 | $10.58M 10-K · filed 2021-02-16 | $20.02M derived: sum of 2 quarters · filed 2021-02-16 | $29.25M derived: sum of 3 quarters · filed 2021-02-16 | |
| 2019-05-31 | $9.44M 10-K · filed 2021-02-16 | $18.67M derived: sum of 2 quarters · filed 2021-02-16 | ||
| 2019-02-28 | $9.23M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |